Last reviewed · How we verify
oral contraceptive pills
Oral contraceptive pills prevent pregnancy by suppressing ovulation through hormonal inhibition of the hypothalamic-pituitary-gonadal axis.
Oral contraceptive pills prevent pregnancy by suppressing ovulation through hormonal inhibition of the hypothalamic-pituitary-gonadal axis. Used for Contraception / prevention of pregnancy, Regulation of menstrual cycles, Treatment of acne.
At a glance
| Generic name | oral contraceptive pills |
|---|---|
| Also known as | yasmin |
| Sponsor | Kayseri Education and Research Hospital |
| Drug class | Hormonal contraceptive |
| Target | Estrogen receptor, Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Oral contraceptives contain synthetic estrogen and/or progestin that inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, preventing ovulation. Additionally, they thicken cervical mucus and alter the endometrium to create a hostile environment for sperm and implantation.
Approved indications
- Contraception / prevention of pregnancy
- Regulation of menstrual cycles
- Treatment of acne
- Management of polycystic ovary syndrome (PCOS) symptoms
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
- Hypertension
Key clinical trials
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (PHASE1)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
- Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
- The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.
- Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR (PHASE2)
- Combined Oral Contraceptive Pill and Resistance Starch (PHASE2)
- Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation (NA)
- Role of Estrogen on Skeletal Outcomes in FHA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral contraceptive pills CI brief — competitive landscape report
- oral contraceptive pills updates RSS · CI watch RSS
- Kayseri Education and Research Hospital portfolio CI